While OS is still the king of the oncology endpoints, experts note it may soon be phased out due to the introduction of ...

Endpoint protection, often abbreviated as EPP, is a system designed to secure each endpoint of an enterprise network from potential cyber threats. It's a security approach that focuses on each device ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Johnson & Johnson announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted ...

This article is part of a VB special issue. Read the full series here: Intelligent Security Achieving greater visibility and control over endpoints is table stakes for any organization pursuing ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ...

Skye Bioscience (SKYE) announced the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, its ...

The rapid pace of digital transformation has increased operational efficiency and enhanced the customer experience – but it has also created a nightmare for CISOs. From mobile devices scattered across ...